SCHEMBL1716332

SCHEMBL1716332

CC(C)(C)OC(=O)Nc1ncc(-c2nnnn2Cc2ccccc2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.46
HTT P42858 2/20 0.44
USP30 Q70CQ3 1/20 0.43
TSHR P16473 3/20 0.43
GHSR Q92847 1/20 0.43
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
BRD4 O60885 1/20 0.42
CCNE1 P24864 1/20 0.42
CDK2 P24941 1/20 0.42
CDK5 Q00535 1/20 0.42
SCD O00767 1/20 0.42
HDAC6 Q9UBN7 3/20 0.41
CYP2C9 P11712 1/20 0.41
PTGER1 P34995 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
HDAC3 O15379 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1715313 0.78 PSEN1 (0.58) KMT2AHTTUSP30
SCHEMBL28014843 0.77 KDR (0.62) USP30CCNE1CDK2CDK5SCD
SCHEMBL5767787 0.74 CSNK2A2 (0.53) BRD4CCNE1CDK2CDK5CYP2C9
SCHEMBL25524186 0.74 PIM1 (0.44) KMT2AALDH1A1CCNE1CDK2CDK5
SCHEMBL12027281 0.73 CCNE1 (0.51) KMT2AHTTTSHRALDH1A1PKM
SCHEMBL1260011 0.71 MAPK1 (0.42) CCNE1CDK2CDK5MAPK1
SCHEMBL12715491 0.71 LCK (0.46) CCNE1CDK2CDK5SCD
SCHEMBL16989187 0.71 MAPK1 (0.43) KMT2AHTTALDH1A1CCNE1CDK2
SCHEMBL8283721 0.70 PPARA (0.52) KMT2AHTTALDH1A1CCNE1CDK2
SCHEMBL16989145 0.69 MAPK1 (0.42) HTTCCNE1CDK2CDK5SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709018-B1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS SANOFI AVENTIS (FR) 2011-07-20 EP disclosed
EP-1709018-B1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS SANOFI AVENTIS (FR) 2011-07-20 EP disclosed
US-7759377-B2 Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-7759377-B2 Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-7759377-B2 Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-20080176911-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS SANOFI-AVENTIS (FR) 2008-07-24 US disclosed
US-20080176911-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS SANOFI-AVENTIS (FR) 2008-07-24 US disclosed
US-20080176911-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS SANOFI-AVENTIS (FR) 2008-07-24 US disclosed
US-7371770-B2 Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors SANOFIAVENTIS (FR) 2008-05-13 US disclosed
US-7371770-B2 Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors SANOFIAVENTIS (FR) 2008-05-13 US disclosed
US-7371770-B2 Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors SANOFIAVENTIS (FR) 2008-05-13 US disclosed
US-20060293366-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS SANOFI-AVENTIS (FR) 2006-12-28 US disclosed
EP-1709018-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS Sanofi-Aventis (FR) 2006-10-11 EP disclosed
WO-2005073202-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS SANOFI-AVENTIS (FR) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176911-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS APP, BACE1, ATG4A KMT2A 1656/4885HTT 11/4885USP30 3301/4885
US-20060293366-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS APP, BACE1, ATG4A KMT2A 1656/4885HTT 11/4885USP30 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.